A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.32964
Abstract: Regorafenib is an oral multikinase inhibitor targeting angiogenesis, oncogenesis, and cancer proliferation/metastasis. This study evaluated the efficacy of regorafenib in refractory biliary tract cancer (BTC) in a multi‐institutional phase 2 study. read more here.
Keywords: biliary tract; regorafenib refractory; tract cancer; multi institutional ... See more keywords